Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)

Xiangxue Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	131.74	149.32	166.5	196.12	605.21
Short-Term Investments	13	-	-	105.42	38
Trading Asset Securities	-	-	0.13	65.63	19.34
Cash & Short-Term Investments	144.74	149.32	166.63	367.17	662.55
Cash Growth	-3.06%	-10.39%	-54.62%	-44.58%	26.38%
Accounts Receivable	844.23	794.44	701.7	1,220	1,226
Other Receivables	57.53	52.55	76.47	346.04	733.59
Receivables	901.76	846.99	778.17	1,566	1,960
Inventory	340.92	411.3	467.07	761.46	839.81
Other Current Assets	215.28	416.74	281.32	390.9	269.15
Total Current Assets	1,603	1,824	1,693	3,086	3,731
Property, Plant & Equipment	4,260	4,621	4,808	5,957	5,431
Long-Term Investments	123.44	178.48	472.03	270.21	443
Goodwill	199.72	199.72	199.72	266.6	626.61
Other Intangible Assets	840.4	919.28	964.09	1,034	1,084
Long-Term Deferred Tax Assets	19.66	28.42	33.35	19.37	21.23
Long-Term Deferred Charges	248.82	476.81	440.65	429.51	395.46
Other Long-Term Assets	203.74	33.08	30.95	318	463.62
Total Assets	7,498	8,281	8,642	11,381	12,197
Accounts Payable	1,154	1,087	988.95	1,123	801
Accrued Expenses	228.41	116.84	112.39	72.82	61.78
Short-Term Debt	1,355	1,498	1,926	2,466	2,881
Current Portion of Long-Term Debt	282.98	340.33	76.73	447.6	134.03
Current Portion of Leases	3.35	3.63	3.25	2.9	-
Current Income Taxes Payable	21.73	15.16	8.14	9.1	12.58
Current Unearned Revenue	152.94	162.81	249.79	117.38	85.01
Other Current Liabilities	2,184	1,938	1,868	2,705	2,827
Total Current Liabilities	5,382	5,162	5,233	6,944	6,802
Long-Term Debt	570.64	556	426.93	528.92	946.92
Long-Term Leases	30.88	34.92	24.92	2.36	-
Long-Term Unearned Revenue	53.18	60.42	60.35	65.65	75.66
Long-Term Deferred Tax Liabilities	8.12	9.46	6.62	3.73	0.02
Other Long-Term Liabilities	14.74	144.92	170.06	77.86	122.51
Total Liabilities	6,060	5,967	5,922	7,623	7,947
Common Stock	661.28	661.28	661.28	661.36	661.48
Additional Paid-In Capital	2,152	2,152	2,152	2,152	2,142
Retained Earnings	-1,731	-882.06	-493.1	138.42	825.73
Treasury Stock	-8.5	-8.5	-8.5	-8.77	-20.49
Comprehensive Income & Other	-19.28	1.69	-5.19	2.07	4.2
Total Common Equity	1,055	1,925	2,307	2,946	3,613
Minority Interest	383.93	388.52	413.22	812.23	636.5
Shareholders' Equity	1,439	2,313	2,720	3,758	4,249
Total Liabilities & Equity	7,498	8,281	8,642	11,381	12,197
Total Debt	2,243	2,433	2,458	3,448	3,962
Net Cash (Debt)	-2,098	-2,284	-2,291	-3,081	-3,300
Net Cash Per Share	-3.18	-3.46	-3.46	-4.65	-5.03
Filing Date Shares Outstanding	661.74	645.14	659.23	958.52	607.92
Total Common Shares Outstanding	661.74	645.14	659.23	958.52	607.92
Working Capital	-3,779	-3,337	-3,540	-3,858	-3,071
Book Value Per Share	1.59	2.98	3.50	3.07	5.94
Tangible Book Value	14.78	805.7	1,143	1,645	1,902
Tangible Book Value Per Share	0.02	1.25	1.73	1.72	3.13
Buildings	3,864	3,442	3,495	3,709	1,832
Machinery	990.74	1,043	1,040	946.22	911.88
Construction In Progress	614.63	1,214	1,180	2,106	3,426

Source: S&P Global Market Intelligence. Standard template. Financial Sources.